Healthcare Professional Check

This website is intended for diabetes healthcare professionals. Click one of the options below to access the content.

You are here

New Fixed Ratio Basal – Bolus Insulin Combination Therapy for Diabetes Specialists

for Diabetes Specialists

This course reviews the rationale for combining basal insulin and rapid-acting insulin analogues and highlights some important safety aspects of this treatment approach. It describes how control of fasting plasma glucose and postprandial glucose can be achieved with new fixed-ratio basal and rapid-acting insulin analogue combination. Guidance is provided that is intended to help you identify appropriate patients for these flexible and convenient combination.

Course contents

  • Webcast

    New Fixed-Ratio Basal–Bolus Insulin Combination Therapy

    • Matching treatment to disease progression
    • Contribution of FPG and PPG to HbA1c
    • Challenges of conventional basal–bolus treatments (basal plus) and premixed insulin analogues
    • What are the different treatment intensification options
    • Rationale for combining basal and bolus insulin
    • Efficacy and safety profile of new fixed ratio basal–bolus insulin combinations in T1D and T2D
    • Convenience, flexibility, and clinical indications for new fixed ratio basal–bolus insulin combinations
  • Roundtable

    Hypoglycaemia: risk factors, current management, and controversies

    • Definition of hypoglycaemia: what is severe hypoglycaemia?
    • Impact of hypoglycaemia
    • Risk factors associated with hypoglycaemia
    • Strategies to reduce hypoglycaemia
  • Selected article

    ​The Distinct Prandial and Basal Pharmacydynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

  • Selected article

    Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

  • Selected article

    Treatment intensification with an insulin degludec (Ideg/insulin aspart (Iasp) co-formulation twice daily compared with basal Ideg and prandial Iasp in type 2 diabetes: a randomized, controlled phase III trial

Courses are now online!

Register for the Insulin Educational program and start any available content whenever you want. You can sign up to the E-alert list to be notified when new courses or course modules are uploaded.

Search this site

Search form


Developed by Elsevier B.V., supported by an unrestricted educational grant from Novo Nordisk